title: Inhibitory phosphorylation of PP1alpha catalytic subunit during the G(1)/S transition.
abstract: We have shown earlier that, in cells expressing the retinoblastoma protein (pRB), a protein phosphatase (PP) 1alpha mutant (T320A) resistant to inhibitory phosphorylation by cyclin-dependent kinases (Cdks) causes G(1) arrest. In this study, we examined the cell cycle-dependent phosphorylation of PP1alpha in vivo using three different antibodies. PP1alpha was phosphorylated at Thr-320 during M-phase and again in late G(1)- through early S-phase. Inhibition of Cdk2 led to a small increase in PP1 activity and also prevented PP1alpha phosphorylation. In vitro, PP1alpha was a substrate for Cdk2 but not Cdk4. In pRB-deficient cells, phosphorylation of PP1alpha occurred in M-phase but not at G(1)/S. G(1)/S phosphorylation was at least partially restored after reintroduction of pRB into these cells. Consistent with this result, PP1alpha phosphorylated at Thr-320 co-precipitated with pRB during G(1)/S but was found in extracts immunodepleted of pRB in M-phase. In conjunction with earlier studies, these results indicate that PP1alpha may control pRB function throughout the cell cycle. In addition, our new results suggest that different subpopulations of PP1alpha regulate the G(1)/S and G(2)/M transitions and that PP1alpha complexed to pRB requires inhibitory phosphorylation by G(1)-specific Cdks in order to prevent untimely reactivation of pRB and permit transition from G(1)- to S-phase and/or complete S-phase.
authors.affiliation: Division of Hematology/Oncology, Childrens Hospital Los Angeles, University of Southern California School of Medicine, Los Angeles, California 90027, USA.
authors.forename: C W
authors.initials: CW
authors.lastname: Liu
authors.forename: R H
authors.initials: RH
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Dohadwala
authors.forename: A H
authors.initials: AH
authors.lastname: Schönthal
authors.forename: E
authors.initials: E
authors.lastname: Villa-Moruzzi
authors.forename: N
authors.initials: N
authors.lastname: Berndt
mesh_terms: D042846:CDC2-CDC28 Kinases; D002453:Cell Cycle; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016193:G1 Phase; D006801:Humans; D015151:Immunoblotting; D007701:Kinetin; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010766:Phosphorylation; D010769:Phosphothreonine / Q000378:metabolism; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011687:Purines / Q000494:pharmacology; D011994:Recombinant Proteins / Q000378:metabolism; D016160:Retinoblastoma Protein / Q000378:metabolism; D016196:S Phase; D014407:Tumor Cells, Cultured
chemical_list: D004791:Enzyme Inhibitors; D011687:Purines; D011994:Recombinant Proteins; D016160:Retinoblastoma Protein; D010769:Phosphothreonine; C090046:olomoucine; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases; D010749:Phosphoprotein Phosphatases; D007701:Kinetin